Benign Prostatic Hyperplasia: Why an Enlarged Prostate Blocks Urine

The normal setup: a gland built around a pipe

To understand why BPH obstructs urine, start with the geography. The prostate is a walnut-sized gland (normally ≈ 20 g, ~15–25 mL) sitting just below the bladder. The prostatic urethra — the first segment of the male urethra — runs straight through its middle. In effect, the outflow pipe from the bladder passes through the substance of the gland, so anything that thickens the gland encroaches on the lumen.

Anatomists divide the prostate into zones (McNeal). Two matter here: the peripheral zone (the bulk of the back of the gland, where most cancers arise) and the transition zone, a small central pair of lobes hugging the urethra. BPH is fundamentally a disease of the transition zone and periurethral tissue — precisely the tissue in closest contact with the pipe. That is why a gland only modestly enlarged overall can still choke the urethra: the growth is happening right where it does the most damage.

Normal voiding requires two things to relax in coordination: the bladder-neck/prostatic smooth muscle (an internal sphincter rich in α₁-adrenergic receptors) opens, and the detrusor (bladder wall) contracts to push urine out. Sympathetic tone keeps that internal sphincter and prostate smooth muscle contracted at rest. Hold that receptor fact — it becomes the whole rationale for the fastest-acting BPH drug.

What goes wrong: hyperplasia, not hypertrophy

The name is a subtle teaching point. It is hyperplasia — an increase in cell number — not hypertrophy (bigger cells). Under the microscope you see nodular proliferation of both glandular epithelium and stroma (smooth muscle + fibrous tissue) in the transition zone. It is a true benign neoplastic-like overgrowth, and it is not a precursor to prostate cancer.

The driver is hormonal and age-dependent. Within prostate cells, the enzyme 5α-reductase (type 2) converts testosterone into dihydrotestosterone (DHT), a far more potent androgen at the prostate. DHT binds the androgen receptor and drives proliferation of transition-zone cells over decades. Two facts anchor this:

1. Men castrated before puberty or with congenital 5α-reductase deficiency essentially never develop BPH — no DHT, no growth.
2. Blocking 5α-reductase pharmacologically shrinks the gland by roughly 20–30% over 6–12 months. Androgens don't cause a sudden tumor; they permit slow, cumulative overgrowth.

Aging estrogen/androgen ratio shifts, altered stromal–epithelial signaling, and chronic low-grade inflammation are additional contributors, but the DHT axis is the therapeutic lever.

The causal chain: from bigger gland to blocked stream

Obstruction in BPH has two components, and confusing them is the classic student error.

1. Static (mechanical) component: the enlarged transition-zone tissue physically narrows and distorts the prostatic urethra. Bulk matters — but so does where it grows; a median lobe can flap over the bladder neck like a ball-valve.
2. Dynamic (functional) component: α₁-mediated smooth-muscle tone in the prostate, capsule and bladder neck actively clamps the lumen. This component can be a large share of the total obstruction and is independent of gland size.

Downstream, the bladder must generate higher pressures to force urine past the resistance. Over months to years the detrusor hypertrophies (visible as trabeculation on cystoscopy) and becomes irritable and poorly compliant. This is the paradox patients don't expect: an obstructive problem produces prominent irritative symptoms — urgency, frequency, nocturia — because the thick, overworked bladder contracts prematurely and holds less. Eventually the detrusor can decompensate, failing to empty, leaving a rising post-void residual and setting the stage for retention.

How it presents: LUTS, and the two symptom families

BPH manifests as lower urinary tract symptoms (LUTS), traditionally split into two groups (the older label "prostatism" is now discouraged because the same symptoms have many causes):

• Voiding/obstructive: weak/slow stream, hesitancy (waiting to start), straining, intermittent stream, terminal dribbling, sensation of incomplete emptying. These reflect the outflow resistance.
• Storage/irritative: urinary frequency, urgency, and — the symptom that most often drives men to the clinic — nocturia (waking to void). These reflect the hypertrophied, overactive bladder.

Symptom severity is quantified with the International Prostate Symptom Score (IPSS): seven questions, total 0–35, graded mild 0–7, moderate 8–19, severe 20–35, plus a bother/quality-of-life item. Two clinical points to remember: symptom severity correlates poorly with gland size (a small gland with high dynamic tone can be miserable; a huge gland can be nearly silent), and LUTS are not specific to BPH — nocturnal polyuria, diabetes, diuretics, heart failure and sleep disturbance all mimic it.

Diagnosis: exam, labs, and knowing when to worry

Workup is largely bedside. On digital rectal exam (DRE), BPH classically feels smooth, symmetric, rubbery and enlarged with a preserved median groove. Any hard, irregular nodule or asymmetry shifts suspicion toward cancer and warrants urology referral.

Key tests:

• Urinalysis — mandatory, to exclude infection, glucosuria, and hematuria (which needs its own malignancy workup).
• PSA — often mildly elevated in BPH roughly in proportion to gland volume; it is not diagnostic of cancer but guides risk and can predict progression. A larger gland (and higher PSA) also identifies men who benefit most from 5α-reductase inhibitors.
• Serum creatinine / eGFR — to detect obstructive (post-renal) kidney injury.
• Uroflowmetry — a peak flow rate (Qmax) below ~10 mL/s (with an adequate voided volume) suggests significant obstruction; ≥15 mL/s makes it unlikely.
• Post-void residual (bladder ultrasound) — persistently high residuals (e.g. >100–200 mL) flag incomplete emptying and retention risk.

Red flags demanding urgent action: painful inability to void (acute urinary retention), a palpable distended bladder, gross hematuria, recurrent UTIs, bladder stones, or a rising creatinine — the last signaling high-pressure chronic retention with post-renal acute kidney injury, a genuine emergency requiring catheter decompression.

Management and natural history: why the drugs work and what happens if ignored

Treatment maps directly onto the two obstruction components:

• α₁-adrenergic blockers (tamsulosin, alfuzosin, silodosin, doxazosin) relax prostatic and bladder-neck smooth muscle, attacking the dynamic component. They work within days and improve flow regardless of gland size. Watch for orthostatic dizziness and intraoperative floppy iris syndrome during cataract surgery.
• 5α-reductase inhibitors (finasteride, dutasteride) block DHT synthesis, shrinking the gland ~20–30% and attacking the static component — but they take 3–6+ months and are most useful in larger glands. They roughly halve the PSA, so double the measured value when screening. Combination therapy outperforms either drug alone (as shown in the MTOPS and CombAT trials) for men at risk of progression.
• Surgery — TURP (transurethral resection) remains the reference standard, physically removing obstructing transition-zone tissue; newer options include laser enucleation, UroLift and Rezūm. Indicated for refractory symptoms, retention, recurrent UTIs/stones, hematuria, or renal impairment.

Natural history if untreated: most men remain stable or slowly progress, but obstruction can advance to acute urinary retention, bladder stones, recurrent infection, an irreversibly decompensated "end-stage" bladder, and hydronephrosis with renal failure. A practical caution: certain drugs (anticholinergics, decongestants/α-agonists, opioids) can precipitate acute retention in a marginally compensated BPH bladder — a common, avoidable trigger.

BPH vs prostate cancer vs prostatitis — three common causes of prostate/voiding trouble that are frequently confused

Feature	BPH	Prostate cancer	Acute prostatitis
Origin zone	Transition zone (periurethral)	Peripheral zone (posterior)	Whole gland (infection)
Onset	Gradual, years	Often silent early; later obstructive	Sudden, hours–days
Digital rectal exam	Smooth, symmetric, rubbery, enlarged	Firm, nodular, or asymmetric	Boggy, warm, exquisitely tender
PSA	Mildly ↑ (proportional to volume)	Can be markedly ↑; abnormal kinetics	Sharply ↑ during infection
Systemic signs	None	None early; bone pain if metastatic	Fever, chills, dysuria, malaise
Key management	α-blocker, 5-ARI, TURP	Surveillance, surgery, radiation, ADT	Antibiotics (avoid vigorous DRE)